SubjectWell Competitors

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 38,000 trials and 12 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC.

WCG is a true partner to research sponsors, CROs, sites and participants in navigating the clinical research journey. The pioneer of independent ethical review, now the industry gold standard, WCG’s 55-year legacy of independent review solutions serves as the foundation on which we continually build to accelerate and improve the clinical research journey. We lead the way by reimagining processes, optimizing quality and safety, strengthening productivity, and pioneering new solutions that leverage data and technology to accelerate research and impact global health. WCG liberates study stakeholders from the constraints that risk trial efficacy while improving quality outcomes and efficiency through the process. Ninety percent of all clinical trials leverage our knowledge, highly specialized solutions, and data-driven insights to mitigate risk today for a more promising tomorrow.

Science 37 is a modern clinical research site that delivers trials directly to patients’ homes. With nationwide reach and medical licensure across all 50 states, its Direct-to-Patient Site enables sponsors to expand access, improve retention, and enroll more representative patient populations compared to relying solely on a traditional site-based approach. Science 37 operates under a single Form FDA 1572 and a central IRB, supported by centralized medical oversight, research-grade nursing, and specialized direct-to-patient clinical operations. The company has successfully completed multiple FDA inspections, resulting in FDA approvals, achieving No Action Indicated (NAI) classifications with zero Form 483 observations. With more than a decade of experience, Science 37 has supported over 200 clinical trials across Phases I–IV and observational studies. Its model consistently delivers strong performance, including approximately 86% completion rates and contributing an average of 20–30% of total study enrollment as a single site. These outcomes have been validated by the Tufts Center for the Study of Drug Development (Tufts CSDD). To learn more, visit www.science37.com or email science37@science37.com.